Supernus Q2 Revenue Surges 32%, but a $54.9M Impairment Drives Net Loss; Full-Year Guidance Lifted
SUPN sits 64% above its 52-week low of $32.83.
Summary
Supernus posted Q2 2026 revenue of $219.1 million (+32% YoY) and raised its full-year outlook, but a $54.9 million APOKYN impairment charge led to a net loss of $58.4 million. The filing also discloses the pending merger with Indivior Pharmaceuticals.
Key Events · Earnings and Guidance · SUPN
-
Q2 Revenue +32% to $219.1M
Driven by Qelbree ($89.2M, +15%), ONAPGO ($13.5M, +745%), and ZURZUVAE collaboration revenue ($35.4M), total revenues climbed 32% year-over-year to $219.1 million.
-
Full-Year Guidance Raised
Citing momentum across the commercial portfolio, management lifted full-year 2026 revenue guidance.
-
$54.9M APOKYN Impairment Charge
A non-cash impairment charge of $54.9 million was taken on the APOKYN intangible asset, reflecting declining sales and a reduced long-term outlook for the brand.
-
Net Loss of $58.4M
Despite the robust revenue growth, the impairment charge and higher operating expenses produced a Q2 net loss of $58.4 million, or $1.01 per share.
Analysis · SUPN · Life Sciences
Strong top-line momentum carried Q2 revenue to $219.1 million, a 32% year-over-year increase fueled by Qelbree, ONAPGO, and ZURZUVAE collaboration revenue. Reflecting that commercial confidence, management raised full-year revenue guidance. Yet a $54.9 million non-cash impairment charge on the APOKYN intangible asset—a legacy Parkinson's drug with a deteriorating sales outlook—pushed the bottom line to a net loss of $58.4 million. The filing also flags the August 1, 2026 all-stock merger agreement with Indivior Pharmaceuticals as a subsequent event, a transformative deal that will forge a CNS biopharma leader with $2.2 billion in combined revenue. For investors sizing up the standalone business ahead of the combination, the raised guidance and the impairment charge take on added significance.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SUPN was trading at $53.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $32.83 to $59.68. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.